Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy